Blood thickness in severe lung injury
Part of Lungs & breathing clinical trials.
This study looks at how thick your blood is to see if it plays a role in ARDS, a severe lung injury that makes breathing very difficult. It may help doctors understand the condition better and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have moderate to severe ARDS (a serious lung condition) diagnosed by a doctor.
- Your ARDS should have started within the last 72 hours.
- You must not have had a blood transfusion in the last month.
- You must not have certain blood diseases (like leukemia or lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test measuring fibrinogen and albumin levels can help predict if someone with a traumatic brain injury will develop a serious lung condition called acute respiratory distress syndrome (ARDS). It may help doctors identify patients who need extra monitoring and care.
This study uses a special blood test (called NMR metabolomics) to understand how your body's chemistry changes in the early stages of mild ARDS. It may help find better ways to treat this serious lung condition.
This study looks for proteins in the blood that might help doctors detect a rare lung injury caused by blood transfusions. It uses blood samples from ICU patients to compare those with and without lung problems.
This study checks if certain blood tests can predict which patients with severe chest injuries will develop serious breathing problems or die. Doctors will take blood samples soon after injury to see if these markers help identify high-risk patients early.
This study looks at different patterns in patients with a severe lung condition called ARDS, to better understand why some respond to treatments differently. You may help doctors learn how to personalize care.
This study looks at a blood marker (EV-TF) to see whether it helps predict pulmonary embolism—blood clots in the lungs—in people with ARDS who are in the ICU. Results may help doctors better identify who is at higher risk.
Hear when a new ARDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.